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ABSTRACT 
Purpose 
Although cigarette smoking is a well-established risk factor for urothelial cancer (UC), its 
role in UC prognosis is still undetermined. This meta-analysis aimed to quantify the role of 
lifetime smoking history on bladder cancer recurrence, progression and survival, by pooling 
available data on non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder 
cancer (MIBC) and upper tract urothelial carcinoma (UTUC). 
Materials and methods 
A total of 24 studies, comprising data from 13,114 BC and 2,259 UTUC patients, were 
included in this meta-analysis. Publication bias was addressed through Eggers test and the 
heterogeneity between studies was assessed by the I2 test statistic and subgroup analyses. 
Results 
Current smokers at diagnosis are at an increased risk of developing local recurrences in 
NMIBC (HR=1.27, 95% C.I. = 1.09-1.46) and smoking MIBC patients are at an increased 
risk of dying due to BC (HR=1.23, 95% C.I. = 1.02-1.44). In the UTUC population smokers 
have both an increased risk of recurrence in the operative bed (HR=1.57, 95%C.I. = 1.19-
1.95) and of dying due to UTUC (HR=1.53, 95%C.I. = 1.13-1.92). We did not identify 
significant heterogeneity between included studies. 
Conclusions 
The body of evidence is limited due to the absence of prospective studies. However, the 
results from this meta-analysis unambiguously support the hypothesis that lifetime cigarette 
smokers are at an increased risk of developing a more malignant type of urothelial carcinoma 
associated with worse prognosis.  
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1. PURPOSE 
Smoking is a major risk factor for the development of urothelial cancer as has been shown 
repeatedly in several case-control and cohort studies (1). However, there has been little 
research into the influence of smoking status at diagnosis, and continuation of smoking after 
diagnosis, on urothelial cancer recurrence, progression and survival. Several reviews have 
highlighted the potential effect that smoking status might have on disease recurrence in non-
muscle-invasive bladder cancer (NMIBC) and possibly progression to muscle-invasive 
bladder cancer (MIBC) (2-4) as well as worse upper tract urothelial carcinoma (UTUC) 
prognosis (2, 5). 
Lifetime smoking history seems to be associated with increased tumour size and 
aggressiveness of disease at first diagnosis (4, 6). However, it remains unclear whether this is 
also reflected in different clinical outcomes from urothelial carcinoma (UC), a definition 
which encompasses both BC and UTUC, for patients who are smokers compared to never 
smokers. It is suggested that current smokers at diagnosis have higher NMIBC local 
recurrence rates compared to never smokers (2, 3). However, this association or the 
potentially significant association with disease progression has never been previously 
summarised in a meta-analysis. 
This study aimed to quantify the role of lifetime smoking history on UC recurrence, 
progression and survival, by meta-analysis of available data on NMIBC, MIBC and UTUC. 
By quantifying the associations between lifetime smoking status and UC prognosis, this study 
will shed more light on whether smoking status should be incorporated in prognostication of 
BC and UTUC in clinical as well as non-clinical settings. 
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2. MATERIALS AND METHODS 
2.1. Search strategy 
Medline, Embase, Web of Science and Scopus were used to search for studies on cigarette 
smoking and bladder cancer recurrence, progression and bladder-cancer related mortality. 
The search was restricted to only include studies involving humans and there was no 
restriction with regard to publication date. Search terms included the (MeSH) terms “urinary 
bladder neoplasms”, “neoplasm recurrence” “survival”, “smoking” and “epidemiologic 
studies” which resulted in 1,528 hits on possible articles to include after removal of 
duplicates. Studies were excluded when no hazard ratio (HR) for either recurrence-free, 
progression-free or disease-free survival for smoking status (current and former versus never 
smokers) was given. Disease recurrence had to be specified as local recurrence for NMIBC 
and MIBC and as recurrence in the operative bed of the tumour for UTUC. Furthermore, only 
studies which regarded never smokers as the reference category for calculation of HRs were 
included. Moreover, only studies which provided information or stratified for received 
therapy were included to avoid misinterpretation due to the effects of different therapies.  
2.2. Data collection 
To assess the risk of bias and identify possible sources of heterogeneity within individual 
studies selected for full text evaluation the Newcastle-Ottowa assessment scale (NOS) for 
cohort studies was applied (7) by two of the authors (FvO and SJ). Several variables were 
extracted from included articles including year of publication, geographic area, disease type 
(NMIBC, MIBC or UTUC), cigarette smoking assessment (questionnaire, interview or 
patient records), factors adjusted for and median length of follow-up time. HRs were obtained 
directly from included articles and were divided in recurrence-free (RFS), progression-free 
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(PFS) and disease-specific (DSS) survival HRs. When bladders were resected in MIBC 
populations, recurrence-free survival was specified by loco-regional recurrence; recurrence at 
the margins of the surgical field or in the lymph nodes. 
2.3. Statistical analysis 
HRs were pooled comparing RFS, PFS and DSS for current and former smokers to never 
smokers in NMIBC, MIBC and UTUC patients. Because HRs could differ between studies, a 
random effects model was used to model potential heterogeneity. The I2 test statistic was 
used to estimate between-study variance. Furthermore, meta-regression analysis was 
performed to estimate the effect of possible sources of heterogeneity (smoking assessment, 
factors adjusted for, length of follow-up) on different outcome measures. Publication bias 
was explored by funnel plots and Egger’s test for small study effects for the different 
analyses performed (8). Unfortunately, there was insufficient data to also stratify for gender. 
Subgroup analyses were performed comparing pooled HRs across geographic area, length of 
follow-up quartile, study design and smoking assessment where possible. Stata statistical 
software was used for all analyses (version 13; Stata Corp., College Station, TX). 
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3. RESULTS 
3.1. Study characteristics 
In total, 24 studies were included in this meta-analysis; 11 for NMIBC (9-19) including 7,210 
cases, 7 for MIBC (20-26) investigating 2,259 cases, and 6 for UTUC (27-32) encompassing 
5,904 cases (Table 1). During full-text evaluation 5 studies were excluded because of a lack 
of data in the study report (33-37). Furthermore, 9 articles were excluded during data 
extraction because no HR for smoking status was given (38-42) or because the reference 
category was not comprised of never smokers (43-46) (Figure 1). All included studies were 
patient cohort studies, except for two epirubicin trials in NMIBC (10, 13). The majority of 
studies which included HR estimates regarding smoking and C prognosis were published 
after 2007. Smoking status was assessed either through questionnaires (9, 10, 12-15, 18-20, 
22, 25, 27-32), patient records (11, 21, 23, 24, 26) or an interview (16, 17). All included study 
populations for NMIBC had undergone full transurethral resection of a bladder tumour 
(TURBT) with some recorded to have received Bacillus Calmette–Guérin (BCG) treatment 
(11, 16). For MIBC, only studies in which patient populations had undergone radical 
cystectomy (complete removal of the bladder) could be included, with some populations 
receiving (neo)adjuvant chemotherapy (20, 23, 24, 26). Although radiation therapy is 
becoming more common as an alternative to radical cystectomy (47), no studies investigating 
associations between smoking and outcomes were found in radiation therapy patient 
populations. In included UTUC study populations all patients underwent 
nephroureterectomy. (INSERT TABLE 1 & FIGURE 1 HERE) 
3.2. Risk estimates for smoking status in NMIBC 
Figure 2 summarizes all obtained risk estimates for smoking and RFS and PFS for NMIBC 
and shows the individual study results in forest plots. The pooled HR of 1.27 (95% C.I.=1.09-
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1.46) shows that current smokers at diagnosis are at a slightly increased risk of developing 
local recurrences compared to non-smoking NMIBC patients. A mitigated effect is seen in 
former smokers compared to non-smokers where the pooled HR is 1.13 (95% C.I.=1.00-1.25) 
based on 5,382 NMIBC cases. Similar (but not statistically significant) pooled HRs for PFS 
were obtained for both smokers (HR=1.21, 95% C.I.=0.81-1.61) and former smokers 
(HR=1.13, 95% C.I.=0.81-1.45). With regard to DSS, only two studies investigating 925 
NIMBC cases could be pooled and indicated no effect of being a current smoker at baseline 
(HR=1.01 (95% C.I.=0.93-1.10)). (INSERT FIGURE 2 HERE) 
3.3. Risk estimates for smoking status in MIBC 
Obtained pooled estimates for smoking status in MIBC are summarized and depicted in forest 
plots in Figure 3. With regard to RFS only one of the four included studies reported a 
significantly increased risk of loco-regional recurrence in MIBC for current smokers at 
diagnosis (21), and two of three included studies showed an increased risk of local recurrence 
for former smokers (20, 21). Pooling these studies resulted in a pooled HR for recurrence of 
1.09 (95% C.I.=0.78-1.40) for current smokers and a HR of 1.17 (95% C.I.=0.82-1.52) for 
former smokers compared to non-smokers at diagnosis. For the relation between smoking 
status at baseline and DSS more studies were identified in the literature. Current smokers at 
diagnosis seem to be at a higher risk of dying due to BC compared to non-smokers 
(HR=1.23, 95% C.I. =1.02-1.44), while a similar effect was observed for former smokers 
(HR=1.26, 95% C.I. =0.98-1.54). The HR for current smokers did not seem to differ between 
studies with different follow-up times. (INSERT FIGURE 3 HERE) 
3.4. Risk estimates for smoking status in UTUC 
No published studies on PFS for smokers in UTUC patient populations could be identified. 
Current smokers at diagnosis were at a significantly higher risk of both developing 
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recurrences in the operative bed (HR=1.57, 95%C.I. =1.19-1.95) and dying due to UC 
(HR=1.53, 95%C.I. =1.13-1.92). For former smokers this effect was mitigated, both for RFS 
(HR=1.31, 95% C.I.=0.85-1.78) and DSS (HR=1.20, 95% C.I. =0.80-1.61) (Figure 4). 
(INSERT FIGURE 4 HERE) Although the evidence was too sparse or limited to pool for 
NMIBC and MIBC studies for UTUC there were two similar studies (28, 29) investigating 
smoking duration and intensity before diagnosis on RFS. Results from these studies indicate a 
dose-response relationship between both smoking duration and intensity and RFS in UTUC 
patients (Online supplemental materials – Table 1). 
3.5. Publication bias and heterogeneity between studies 
Both statistically and visually (as judged from several funnel plots), the amount of bias 
between studies seemed negligible within all three different disease categories. However, a 
statistically significant small study effect (p=0.041) was observed for the NMIBC studies 
investigating RFS, indicating that there were no (small) studies published which observed a 
protective effect of smoking. Meta-regression analyses showed that no significant 
heterogeneity was present due to mode of smoking assessment, number of adjusted factors 
(mostly multivariable) or months of median follow-up, and I2 test statistics were all under 
30% except for comparing the five studies investigating RFS in UTUC (78%). 
3.6. Sensitivity analyses 
Subgroup analyses in studies investigating RFS in NMIBC patients and DSS in MIBC 
showed no significant heterogeneity between geographic areas or follow-up quartile and 
study design or smoking assessment respectively between studies (Figure 5). Current smokers 
from Asian populations (16-18) seemed to be at a higher risk of developing local recurrences 
compared to American, European and worldwide populations, although these differences 
were not statistically significant (p=0.452, p=0.447 and p=0.452 respectively). Within all 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
included UTUC studies research methods were homogenous thus results could not be 
stratified for sensitivity analysis. Additional inverse variance weighted regression analyses 
showed no significant change in observed HRs with increasing median follow-up time 
continuously. (INSERT FIGURE 5 HERE). 
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4. DISCUSSION 
This meta-analysis indicates a role for lifetime smoking behaviour in BC and UTUC 
prognosis, showing an increased risk for disease recurrence and increased risk of death for 
current smokers at different stages of BC and UTUC.  
4.1. Significantly higher local recurrence rates for smokers at diagnosis in NMIBC 
Previous reviews have already suggested that current smokers at diagnosis are at an increased 
risk of developing local recurrences compared to non-smokers in NMIBC patient populations 
(2-4); however, this is the first study to quantify these risks. We observed an increased risk of 
developing local recurrences for current smokers compared to never smokers. Former 
smokers had a lower (but still increased) risk of developing local recurrences. These results 
are in-line with other studies indicating a potentially more malignant disease type for smokers 
at diagnosis (4, 6). The associations between smoking status at diagnosis and PFS were 
comparable to the RFS estimates, although not statistically significant.  
In NMIBC, smoking appears to promote recurrences but it is not associated with  
progression/death. Mechanistically, there is thus likely to be an influence of smoking on the 
hallmark capabilities of BC such as self-sufficiency in growth signals and delimiting 
replicative potential (48, 49). Although evidence on the effects of smoking with regard to BC 
prognosis is limited, including smoking status in panels of molecular markers (including e.g. 
p53, cyclooxygenase and vascular endothelial growth factor) has shown to improve 
prognostication in several studies (45, 50). 
4.2. More deaths due to BC in smokers at diagnosis compared to never smokers in 
MIBC 
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Compared to NMIBC there were considerably fewer studies investigating the role of smoking 
in MIBC prognosis, although one other meta-analysis also showed significantly increased BC 
mortality for current smokers compared to never smokers (RR=1.89 95% C.I.= 1.29-2.78) not 
regarding stage of disease (51). We did not demonstrate a relationship between smoking and 
RFS in MIBC patients; however, both current and former smokers at diagnosis are at a higher 
risk of dying due to BC compared to never smokers. There were also noticeably fewer studies 
investigating RFS compared to DSS in MIBC patient populations, emphasizing the need for 
more studies investigating RFS also in MIBC patients. Although there have not been specific 
studies investigating this association biologically or mechanistically, it is possible that the 
higher mortality due to bladder cancer for smokers can be attributed to a more malignant 
subtype of BC at diagnosis, as suggested by other authors (4, 6).  
With regard to smoking and survival in MIBC, there are several malignant processes in 
which smoking is suspected to play a role and which might explain the observed association 
with poor survival. Smokers have been shown to have a significantly higher expression of 
Twist, a transcription factor regulating epithelial-mesenchymal transition which is an 
important event in tumor invasion (52). Also, positive expression of heme-oxygenase-1 (HO-
1) may be dependent on smoking intensity as measured at diagnosis (53). Moreover, it is 
probable that chronic exposure to cigarette smoke induces reduced sensitivity to cisplatin 
treatment, a well-known phenomenon in the management of MIBC (54).  
4.3. Significant associations between smoking and both RFS and DSS in UTUC patients 
Interestingly, current smokers at diagnosis in the UTUC population were approximately at a 
50% increased risk of both RFS and DSS compared to never smokers. Although the number 
of events was the smallest from the three meta-analyses performed, significant associations 
were observed. This indicates that also for UTUC patients, the risk of developing disease 
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recurrences in the operative bed and dying due to UTUC is increased for smokers. Although 
similar associations are observed and many disease characteristics are shared, UTUC is 
considered to be a different disease than BC because there are a number of anatomical, 
biological and molecular-genetic differences (55). For example, microsatellite instability 
(MSI) and hypermethylation are more often observed in UTUC than in BC, which might lead 
to somatic inactivation of DNA mismatch repair genes representing a different pathway of 
initiating events (56). Furthermore, the proportion of tumours that are invasive at diagnosis is 
about 50% for UTUC (57) whereas for BC these numbers are lower at approximately 20-30% 
(58), possibly explaining why the observed associations with RFS and DSS are stronger 
compared to those found in NMIBC and MIBC. 
4.4. Limitations 
Important limitations of this study were the lack of prospective data on smoking behaviour 
after diagnosis, insufficient data to pool for relevant molecular subtypes of NMIBC and the 
lack of more detailed smoking behaviour (such as duration and intensity) before diagnosis in 
survival analyses. Even though current smokers at diagnosis could have quit smoking in the 
period prior to recurrence, dose-response meta-analyses show that smoking cessation only 
results in risk reduction at least 15 years before diagnosis, indicating a long latency effect of 
cigarette smoke in determining UC risk (unpublished results van Osch et al., manuscript 
currently under review). When considering recurrence as an incident event which usually 
occurs within 15 years of diagnosis, looking at lifetime smoking status at diagnosis could be a 
good proxy measure (with relatively high consistency between included studies for the effect 
of smoking on the development of recurrence). The same arguments hold for progression and 
UC mortality events. However, since UC is extremely heterogeneous biologically (59), 
studies prospectively investigating smoking within strata of molecular subtype and stage will 
provide a more thorough quantification of the effect of cigarette smoking in UC prognosis 
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(and could additionally correct for smoking cessation after diagnosis in analyses to further 
enhance the biological plausibility of these results). Furthermore, such studies will be better 
able to address the question whether smoking status should be considered in predictive 
nomograms (e.g. EORTC or CUETO) to improve decision-making in BC treatment. 
5. CONCLUSIONS 
This meta-analysis supports the hypothesis that lifetime cigarette smokers are at an increased 
risk of developing a more malignant type of UC. Smoking NMIBC and MIBC patients at 
diagnosis are at an approximately 25% increased risk of developing local recurrences and 
dying due to BC respectively. Furthermore, smoking UTUC patients are at an approximately 
55% increased risk of both developing recurrences in the operative bed of the tumour and 
dying due to UTUC compared to never smokers. These results indicate a significant role for 
lifetime smoking status in both BC and UTUC prognosis. 
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APPENDIX A – Table & Figure legends 
Table 1. Study characteristics of included studies investigating smoking in bladder cancer 
prognosis, ordered by year of publication 
Figure 1. Flowchart of study selection and reasons for exclusion 
Figure 2. Pooled risk estimates for recurrence-free survival (RFS) and progression-free 
survival (PFS) in non-muscle invasive bladder cancer (NMIBC) including forest plots 
depicting individual study results 
Figure 3. Pooled risk estimates for recurrence-free survival (RFS) and disease-specific 
survival (DSS) in muscle invasive bladder cancer (MIBC) including forest plots depicting 
individual study results 
Figure 4. Pooled risk estimates for recurrence-free survival (RFS) and disease-specific 
survival (PFS) in upper tract urothelial carcinoma (UTUC) including forest plots depicting 
individual study results 
Figure 5. Forest plot depicting summary hazard ratios (HR) for recurrence-free survival 
(RFS) comparing current smokers versus non-smokers in NMIBC (panel a)and disease-free 
survival (DSS) in MIBC (panel b), by geographic area and time of follow-up quartile and 
study design and smoking assessment respectively. The dashed line represents no effect and 
the solid line stands for the overall pooled HR. 
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Table 1. Study characteristics of included studies investigating smoking in bladder cancer prognosis, ordered by year of publication 
Reference First Author Year Country Disease type Number of 
cases 
Type of 
 study 
Length of follow-up 
(median in months) 
Cigarette 
smoking 
assessment 
(9) Grotenhuis 2014 The Netherlands NMIBC 963 cohort 60 Questionnaire 
(10) Wyszynski 2014 USA NMIBC 716 cohort 72 Questionnaire 
(11) Rink 2013 Europe & USA NMIBC 2,043 cohort 49 Questionnaire 
(12) Serretta 2013 Italy NMIBC 395 trial 48 Questionnaire 
(13) Lammers 2011 The Netherlands NMIBC 278 trial 30 Questionnaire 
(14) Segal 2011 Canada NMIBC 718 cohort 36 Questionnaire 
(15) Sfakianos 2011 USA NMIBC 623 cohort 81 Patient records 
(16) Gangawar 2010 India NMIBC 135 cohort 14 Interview 
(17) Chen 2008 Taiwan NMIBC 413 cohort 36 Interview 
(18) Chen 2007 Taiwan NMIBC 256 cohort 38 Questionnaire 
(19) Allard 1995 Canada NMIBC 368 cohort 24 Questionnaire 
(20) Kim 2014 USA MIBC 139 cohort 43 Questionnaire 
(21) da Silva 2013 Europe, Brazil & USA MIBC 642 cohort 34 Patient records 
(22) Lee 2012 Korea MIBC 602 cohort 56 Questionnaire 
(23) Bostrom 2011 USA MIBC 564 cohort   50* Patient records 
(24) Boorjian 2011 Canada & Finland MIBC 1,506 cohort 43 Patient records 
(25) Yafi 2010 Canada MIBC 2,287 cohort 35 Patient records 
(26) Batty 2008 UK MIBC 164 cohort - Questionnaire 
(27) Kluth 2014 Worldwide UTUC 242 cohort 33 Questionnaire 
(28) Xylinas 2014 Worldwide UTUC 519 cohort 37 Questionnaire 
(29) Rink 2013 Turkey UTUC 864 cohort 50 Questionnaire 
(30) Gunay 2013 Japan UTUC 101 cohort   56* Questionnaire 
(31) Hagiwara 2013 Europe & USA UTUC 245 cohort 51 Questionnaire 
(32) Ehdaie 2012 USA UTUC 288 cohort 50 Questionnaire 
* mean length of follow-up in months instead of median length of follow-up 
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NMIBC RFS   PFS 
Determinants 
No. of 
studies 
No. of 
events HR 95% CI   
No. of 
studies 
No. of 
events HR 95% CI 
Smoking status 
  Non-smoker 1.00 Reference 1.00 Reference 
  Former smoker
 
7
A 
1903 1.13 1.00-1.25 4C
 
978 1.13 0.81-1.45 
  Current smoker 10B
 
1723 1.27 1.09-1.46   6D
 
617 1.21 0.81-1.61 
RFS=recurrence free survival, PFS=progression free survival, HR=hazard ratio, CI=confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pooled risk estimates for recurrence-free survival (RFS) and progression-free 
survival (PFS) in non-muscle invasive bladder cancer (NMIBC) including forest plots 
depicting individual study results 
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MIBC RFS   DSS 
Determinants 
No. of 
studies 
No. of 
events HR 95% CI   
No. of 
studies 
No. of 
events HR 95% CI 
Smoking status 
  Non-smoker 1.00 Reference 1.00 Reference 
  Former smoker 3A
 
360 1.17 0.82-1.52 3C
 
402 1.26 0.98-1.54 
  Current smoker 4B
 
1206 1.09 0.78-1.40   6D
 
760 1.23 1.02-1.44 
RFS=recurrence free survival, DSS=disease-specific survival, HR=hazard ratio, CI=confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Pooled risk estimates for recurrence-free survival (RFS) and disease-specific 
survival (DSS) in muscle invasive bladder cancer (MIBC) including forest plots 
depicting individual study results 
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UTUC RFS   DSS 
Determinants 
No. of 
studies 
No. of 
events HR 95% CI   
No. of 
studies 
No. of 
events HR 95% CI 
Smoking status 
  Non-smoker 1.00 Reference 1.00 Reference 
  Former smoker 4 415 1.31 0.85-1.78 2 331 1.20 0.80-1.61 
  Current smoker 5 482 1.57 1.19-1.95   2 330 1.53 1.13-1.92 
RFS=recurrence free survival, DSS=disease-specific survival, HR=hazard ratio, CI=confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Pooled risk estimates for recurrence-free survival (RFS) and disease-specific 
survival (PFS) in upper tract urothelial carcinoma (UTUC) including forest plots 
depicting individual study results 
A C 
B D 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Online Supplemental Table 1. Pooled hazard ratios for recurrence-free survival (RFS) for 
smoking duration and smoking intensity from two multicentre UTUC patient cohorts. 
 
RFS, UTUC 
  n HR 95% C.I. 
Duration (years) 
   0 
 
1.00 ref 
<20 2 1.42 0.94-1.91 
≥20 2 1.58 1.16-2.00 
Intensity (cigarettes per 
day) 
   0 
 
1.00 ref 
<20 2 1.49 1.08-1.91 
≥20 2 1.64 1.15-2.12 
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Key of definitions for abbreviations: 
 
BC = bladder cancer 
C.I. = confidence interval 
CUETO = Spanish Urological Club for Oncological Treatment scoring system 
DSS = disease-specific survival 
EORTC = European Organisation for Research and Treatment of Cancer scoring system 
HR = hazard ratio 
MIBC = muscle-invasive bladder cancer 
NMIBC = non-muscle-invasive bladder cancer 
NOS = Newcastle-Ottowa assessment scale 
PFS = progression-free survival 
RFS = recurrence-free survival 
UTUC = upper tract urothelial carcinoma 
UC = urothelial cancer 
 
 
